Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies | Zendy

Rana Malek | Zendy; Angeline Y. Chong | Zendy; Beatrice Lupsa | Zendy; Andreea O. Lungu | Zendy; Elaine Cochran | Zendy; Maria A. Soos | Zendy; Robert K. Semple | Zendy; James E. Balow | Zendy; Phillip Görden | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies

Author(s) -

Rana Malek,

Angeline Y. Chong,

Beatrice Lupsa,

Andreea O. Lungu,

Elaine Cochran,

Maria A. Soos,

Robert K. Semple,

James E. Balow,

Phillip Görden

Publication year - 2010

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2010-0167

Subject(s) - insulin resistance , autoantibody , insulin receptor , insulin , receptor , medicine , type 2 diabetes , endocrinology , immunology , antibody , diabetes mellitus

Type B insulin resistance belongs to a class of diseases caused by an autoantibody to a cell surface receptor. Blockade of insulin action results in hyperglycemia, hypercatabolism, severe acanthosis nigricans, and hyperandrogenism in women. This rare autoimmune disorder has been treated with various forms of immunosuppression with mixed success.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research